Parexel, a provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through to Commercialization, announced the expansion of its capabilities to optimize drug development and commercialization in Asia/Pacific through a new Hong Kong presence established by its strategic healthcare consulting Health Advances subsidiary.
The opening of Health Advances Asia Limited leverages the firm’s 20+ years of experience in the Asia/Pacific region to help both local and multi-national companies looking to expand their global footprint. Health Advances’ locally-based, multilingual Hong Kong team will be led by Gary Cheng, who joins Health Advances with more than 30 years’ experience in the pharma, biotech, and medtech industries with such companies as Novartis, BD, Chiron Corporation, Alere, and Aventis (acquired by Sanofi). Additionally, Vivek Mittal, a long-time Partner at Health Advances in its San Francisco office, is now also based in Hong Kong and will work closely with Gary and the rest of the team to assist clients with their business needs.
Health Advances provides business strategy, scientific and clinical expertise along with a deep knowledge of product development considerations, referral patterns and economic conditions that can impact the adoption of healthcare products and services. Health Advances’ strategic consulting is a key component of Parexel Biotech, the company’s division focused on helping emerging companies chart the fastest, most-efficient course to accomplish their drug development goals. Health Advances’ local team, along with its more than 160 global employees, will provide strategic consulting support to the healthcare industry across Asia/Pacific, including Greater China, Japan, South Korea, Australia, India and South East Asian Countries.
“For both local companies in Asia/Pacific and global companies looking to expand into the region, taking advantage of the rapid economic growth in the local healthcare market requires thoughtful and strategic business decisions,” said Paula Ness Speers, Health Advances’ Co-Founder and Managing Director. “Building on our long history of helping companies explore and evaluate opportunities in the Asia/Pacific region and assisting locally-based companies looking to expand beyond their borders, we’re excited to have part of our consulting team now based full-time on the ground in the region to readily support customers in this growing market.” She continued, “Under Vivek and Gary’s leadership, our local team is well-equipped to help clients across the healthcare sector, including biopharmaceutical, medtech, diagnostics, health IT and digital health, and healthcare services as well as investors in healthcare businesses understand and capitalize on both local and global opportunities.”
With Health Advances Asia Limited, Parexel now has eight offices, more than 1,700 employees across all functions in Greater China and more than 8,000 employees in the Asia/Pacific region.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.